Predict your next investment

HEALTHCARE | Medical Equipment & Supplies
sonetik.ch

See what CB Insights has to offer

Board of Directors

3

Sonetik Board of Directors

3 Board of directors

Sonetik has 3 board of directors, including Karsten Fischer.

Name

Firm

Work History

Other Seats

Karsten Fischer

AyoxxA Biosystems, Biognosys, Curetis, Humedics, and Ventaleon

Martin Munchbach

Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan, and Glycart. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Masters in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.

Alentis Therapeutics, LAVA Therapeutics, Opsona Therapeutics, Tioga Pharmaceuticals, and Ypsomed

Thomas Möller

Mr. Moeller has strong experience in the valuation of early stage and start-up companies in the life science sector and large multinational organizations. Until 2003 he worked as Chief Financial Officer at NMT New Medical Technologies focusing on private equity investments in biopharmaceutical and biotechnological companies. He was financial advisor in several private biotechnology investments of NMT and responsible for financial aspects of the portfolio companies of NMT. Before joining NMT, he worked from 1992-2001 as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States gaining vast experience in early stage and start-up companies in the life science sector as well as large multinational organizations. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.

Allecra Therapeutics, Eyesense, Humedics, Inotrem, Polyphor, and TriCares

Name

Karsten Fischer

Martin Munchbach

Thomas Möller

Firm

Work History

Dr. Münchbach has been a Managing Partner and Investment Advisor Private Equity at BB Biotech Ventures and Bellevue Asset Management since 2004. He has been an active venture capitalist since the late 90’s investing in life science companies across all stages and types. Prior to joining Bellevue Group, he was Investment Manager at BioMed, HBM, and NMT. Dr. Münchbach’s past and current board assignments include Bellevue’s most successful private biopharmaceutical investments, such as Radius Health, Molecular Partners, Optimer Pharmaceuticals, Axovan, and Glycart. Dr. Münchbach holds a PhD in Protein Chemistry, an MSc in Biochemistry, and a Masters in Industrial Engineering and Management from the Swiss Federal Institute of Technology (ETH), Zürich.

Mr. Moeller has strong experience in the valuation of early stage and start-up companies in the life science sector and large multinational organizations. Until 2003 he worked as Chief Financial Officer at NMT New Medical Technologies focusing on private equity investments in biopharmaceutical and biotechnological companies. He was financial advisor in several private biotechnology investments of NMT and responsible for financial aspects of the portfolio companies of NMT. Before joining NMT, he worked from 1992-2001 as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States gaining vast experience in early stage and start-up companies in the life science sector as well as large multinational organizations. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.

Other Seats

AyoxxA Biosystems, Biognosys, Curetis, Humedics, and Ventaleon

Alentis Therapeutics, LAVA Therapeutics, Opsona Therapeutics, Tioga Pharmaceuticals, and Ypsomed

Allecra Therapeutics, Eyesense, Humedics, Inotrem, Polyphor, and TriCares

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.